doi: 10.18282/amor.v2.i1.121
EDITORIAL
Personalized hormonal treatment for prostate cancer: An opportunity for improvement Omar Abdel-Rahman Clinical Oncology Department, Ain Shams University, Cairo, Egypt
Keywords: prostate cancer; abiraterone acetate; hormonal treatment Citation: Abdel-Rahman O. Personalized hormonal treatment for prostate cancer: An opportunity for improvement. Adv Mod Oncol Res 2016; 2(1):1; http://dx.doi.org/10.18282/amor.v2.i1.121 Correspondence to: Omar Abdel-Rahman, Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lotfy Elsayed Street, Cairo, 113331, Egypt,
[email protected].
Received: 8th December 2015; Accepted: 7th January 2016; Published Online: 19th February 2016
P
rostate cancer is an international health problem and is one of the major causes of cancer morbidity and mortality in men[1]. Hormone sensitivity and responsiveness are considered among the landmark biological features of this disease; thus, they have been exploited extensively in the early as well as advanced stages of the disease[2]. For advanced castrate-resistant prostate cancer, a number of hormonal therapies have been approved, including enzalutamide and abiraterone acetate[3]. However, one of the major challenges for oncologists is how to best personalize and tailor different hormonal therapy options in treating prostate cancer patients. Contrary to breast cancer (where we have the estrogen and progesterone receptors as clear predictive markers for response), similarly well-established markers do not exist for prostate cancer. One potential biomarker involves the detection of androgen-receptor splice variant 7 messenger RNA (AR-V7) in circulating tumor cells, which has been hypothetically linked to enzalutamide and abiraterone acetate’s resistance[4]. However, this hypothesis needs to be confirmed in a large scale prospective study in order to be endorsed for clinical practice. The current issue of AMOR features an interesting article by Mandelkow and co-workers[5], which explores the in vitro activity of abiraterone acetate against the androgen receptor in prostate cancer cells and this may lead to the invention of innovative methods to help personalize the administration of this drug. Advocating the use of personalized therapy in the treatment of prostate
cancer should be the focus of basic and clinical researchers alike as this should, in principle, improve the prognosis of cancer patients.
Conflict of interest The author declared no potential conflict of interest with respect to the research, authorship, and/or publication of this article.
References 1.
2.
3.
4.
5.
Abdel-Rahman O. Combined chemohormonal strategy in hormone-sensitive prostate cancer: A pooled analysis of randomized studies. Clin Genitourin Cancer 2015. doi: 10.1016/j.clgc.2015.12.004 Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (suppl 5): v69-v77. doi: 10.1093/annonc/mdv222 Crawford ED, Stone NN, Evan YY, Koo PJ, Freedland SJ, et al. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology 2014; 83(3): 664-9. doi: j.urology.2013.10.026 Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371(11): 1028-38. doi: 10.1056/NEJMoa1315815 Mandelkow R, Brunnert D, Weiss M, Burchardt M, Stope MB. Lysophosphatidic acid receptor isoforms expression in prostate cancer cells is differentially regulated by the CYP17A1 inhibitor abiraterone and depends on the androgen receptor. Adv Mod Oncol Res 2016. doi: 10.18282/amor.v2.i1.83
Copyright © 2016 Abdel-Rahman O. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
1
